Recent studies and reports have highlighted a troubling association between GLP-1 receptor agonists, including popular weight loss drugs Ozempic and Wegovy, and a range of serious eye conditions, particularly in diabetic patients. The European Medicines Agency (EMA) has confirmed very rare cases of serious eye disorders linked to these medications, warning that users may double their risk of developing conditions such as neovascular age-related macular degeneration (AMD). Patients on GLP-1 treatments may also face an increased likelihood of diabetic retinopathy and other ocular risks, raising significant concerns for those managing diabetes. As health regulators continue their evaluations, there are calls for heightened awareness and monitoring among patients prescribed these therapies.